Dbv Technologies SA (DBVT) Stock AnalysisDBVTDbv Technologies SA

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

DBV Technologies is currently not a strong buy due to its low price of $9.05 and a very low RSI of 24.871, indicating oversold conditions. However, the company has a strong gross margin of 100% and significant cash reserves of $174.9 million, which provide some stability. The main risk is its negative net income, which reached -$50.4 million in Q2 2026, indicating ongoing financial challenges.

9 analysts cover DBVT: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 46.40.